Invention Grant
US08664368B2 Fully human monoclonal antibody to VEGF, preparation method and use thereof
有权
VEGF的完全人单克隆抗体，其制备方法和用途
- Patent Title: Fully human monoclonal antibody to VEGF, preparation method and use thereof
- Patent Title (中): VEGF的完全人单克隆抗体，其制备方法和用途
-
Application No.: US13579218Application Date: 2010-04-16
-
Publication No.: US08664368B2Publication Date: 2014-03-04
- Inventor: Shuhui Wang , Chuan Li , Ying Kan , Xin Tong
- Applicant: Shuhui Wang , Chuan Li , Ying Kan , Xin Tong
- Applicant Address: CN Shanghai
- Assignee: Shanghai Biomabs Pharmaceuticals Co., Ltd.
- Current Assignee: Shanghai Biomabs Pharmaceuticals Co., Ltd.
- Current Assignee Address: CN Shanghai
- Agency: Cesari and McKenna, LLP
- Priority: CN201010125263 20100225
- International Application: PCT/CN2010/000513 WO 20100416
- International Announcement: WO2011/103702 WO 20110901
- Main IPC: C07K16/22
- IPC: C07K16/22 ; C07K16/18 ; C07K14/475 ; A61K39/395
Abstract:
The present invention provides a fully human anti-VEGF monoclonal antibody, the preparation method and use thereof. The fully human anti-VEGF monoclonal antibody is obtained by using antibody phage display technology, which has higher antibody affinity and stronger capacity for inhibiting tumor cell proliferation in comparison with humanized antibody bevacizumab, and can be used to prepare anti-tumor medicines.
Public/Granted literature
- US20130046081A1 FULLY HUMAN MONOCLONAL ANTIBODY TO VEGF, PREPARATION METHOD AND USE THEREOF Public/Granted day:2013-02-21
Information query
